First head-to-head trials of once weekly Fosamax and Actonel therapies
The drug major Merck has launched the first two head-to-head clinical trials that compare the efficacy and tolerability of Fosamax (alendronate) once weekly 70mg and Actonel (risedronate) once-weekly 35mg. Fosamax and Actonel, both bisphosphonates indicated for the treatment of osteoporosis in post menopausal women are co-marketed by Aventis and Procter & Gamble through the Alliance for//...Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR
New Haven, Conn. Yale Cancer Center is proud to announce the launch of a weekly program, Yale Cancer Center Answers on WNPR Connecticut Public Radio. Beginning on National Cancer Survivors Day , June 3, the radio program will air from 6:00 to 6:30 p.m. on Sunday evenings and feature the latest information on cancer care. Co-hosts Edward Chu, M.D. and Ken Miller, M.D....